Abstract: Drug eluting stents (DES) useful for the treatment of restenosis are described. The stents comprise biocompatible polymers and adenosine receptor modulators.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.

Abstract: Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Abstract: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.

Abstract: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Abstract: The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (MRI) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials, carboxymethyl dextran (CM-dextran) is the most efficient in terms of stabilizing the annealed iron oxide nanoparticles and exhibiting contrast effects.

Abstract: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. This invention also relates to a medical device including said biomaterial and to a method of repair or treatment including the filling of cavities in the human face or body.

Abstract: The invention relates to aqueous compositions comprising an anionic surfactant and a hyperbranched polyesteramide having at least one quaternized amine endgroup. The compositions, in particular in the form of shampoo preparations are suited for increasing the volume of hair treated therewith. Furthermore, such compositions provide styling attributes and increase the wet-combability of hair.

Abstract: A kit for treating Oligoovulation and/or Oligomenorrhea and/or Amenorrhea comprising a menstruation inducing composition comprising effective amounts of Vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin B-1, Vitamin B-2, Vitamin B-3, Vitamin B-5, Vitamin B-6, Vitamin B-7, Vitamin B-9, Vitamin B-12, Iron, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Boron, and Choline; and an ovulation regulating composition comprising effective amounts of calcium citrate, and magnesium citrate/aspartate.

Abstract: The invention provides intradialytic parenteral nutrition (IDPN) solutions with low carbohydrate for the treatment of malnutrition in dialysis patients. The IDPN solutions of the invention are particularly advantageous for the treatment of malnutrition in patients who are diabetic or suffer from other glucose management related pathologies or patients who require strict fluid management.

Abstract: Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.

Abstract: Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.

Abstract: Multi-polymer compositions for the transdermal delivery of drugs, such as amine-functional drugs, in a flexible, finite form are described. The compositions comprise a polymer matrix that includes a drug or a pharmaceutically acceptable salt thereof and a polymer matrix comprising acrylic polymer(s), polyisobutylene polymer(s) and styrene-isoprene-styrene block copolymer(s). Methods of manufacturing and methods of using the compositions also are described.

Abstract: A composite material including biocompatible and bioresorbable glass, a biocompatible and bioresorbable matrix polymer and a coupling agent capable of forming covalent bonds. The composite also includes a compatibilizer, where at least 10% of the structural units of the compatibilizer are identical to the structural units of the matrix polymer, and the molecular weight of the compatibilizer is less than 30000 g/mol. The use of this composite, a medical device which includes the composite and a method for preparing the composite are also disclosed.

Abstract: New bodily cooling techniques are provided. In some aspects of the present invention, a new rapidly-evaporating cooling gel or fluid is sprayed or doused over or about an athlete's body and/or worn garments in thermal-reduction-optimized gravitational, diffusion and movement-induced patterns, to maximize cooling during exercise. In some aspects, a worn garment may serve as the matrix or platform for this distribution of the fluid. In other aspects, tuned, heat-absorbing port-controlling devices cause the release of the cooling gel or fluid from distribution tubes or other channels (e.g., integral to the flexible fabric itself) upon local underlying body heat exceeding a threshold, and resealing (halting release) upon body or regional heat dropping below a threshold. In still other aspects, heat-expanding sub-elements rise away from a body heat source toward a wider region for heat release, while other cooled sub-elements descend and exchange places with them, to absorb more body heat.

Abstract: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.

Abstract: In the present disclosure, silver ions, copper ions, quaternary ammonium compounds and cationic drugs such as sulphanilamide, chlorhexidine acetate, etc., used as antibacterial agents are incorporated into fibers, filaments and films through nanoclays. The nanoclays serve as a carrier for the antimicrobial agents and are incorporated into the fiber-forming polymer. In one embodiment, the biocidal metals and organic compounds are incorporated into the clay structure via an ion exchange reaction. Nylon nanocomposite filaments and films based on copper and quaternary ammonium ion modified clays provide 100% antibacterial activity against Gram positive Staphylococcus aureus and Gram negative Escherichia coli bacteria at an optimum clay loading of 0.75% (by weight), and the activity is retained up to 50 washes.

Abstract: The present invention is directed to methods and compositions that are useful in producing, feeding and growing animals. Compositions of the present invention comprise an extracted mineral element composition as disclosed herein. Animal lifespan and production is improved when provided with compositions comprising an extracted mineral element composition.